GSL Biotech LLC, commonly known for its flagship product SnapGene, is a leading provider of molecular biology software solutions headquartered in the United States. Founded in 2013, the company has rapidly established itself in the biotechnology industry, focusing on enhancing DNA sequence visualisation and analysis for researchers worldwide. With a commitment to innovation, GSL Biotech offers unique tools that simplify the design and documentation of molecular cloning experiments. Their software is widely recognised for its user-friendly interface and powerful features, making it an essential resource for scientists in academic and commercial laboratories alike. GSL Biotech's dedication to quality and customer satisfaction has positioned it as a trusted partner in the life sciences sector, contributing to significant advancements in genetic research and biotechnology applications.
How does GSL Biotech LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
GSL Biotech LLC's score of 23 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
GSL Biotech LLC, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is classified as a current subsidiary, and while it inherits data from its corporate family, no specific emissions data or reduction targets have been disclosed. As of now, GSL Biotech LLC has not established any formal climate commitments or reduction initiatives, such as Science-Based Targets (SBTi) or other industry-standard climate pledges. The lack of reported emissions and commitments suggests that the company may still be in the early stages of developing its climate strategy. In the context of the biotechnology industry, companies are increasingly recognising the importance of sustainability and are expected to adopt measures to reduce their carbon footprint. GSL Biotech LLC's future climate commitments will be crucial in aligning with industry standards and addressing the growing concerns surrounding climate change.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
GSL Biotech LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
